BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 26423196)

  • 21. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.
    Ringpis GE; Shimizu S; Arokium H; Camba-Colón J; Carroll MV; Cortado R; Xie Y; Kim PY; Sahakyan A; Lowe EL; Narukawa M; Kandarian FN; Burke BP; Symonds GP; An DS; Chen IS; Kamata M
    PLoS One; 2012; 7(12):e53492. PubMed ID: 23300932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.
    Sheppard HW; Celum C; Michael NL; O'Brien S; Dean M; Carrington M; Dondero D; Buchbinder SP
    J Acquir Immune Defic Syndr; 2002 Mar; 29(3):307-13. PubMed ID: 11873082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevalence of CCR5-Δ32 mutation in a cohort of Saudi stem cell donors.
    Alarifi M; Al-Amro F; Alalwan A; Al-Turki A; Fakhoury H; Atallah N; Al-Muallimi M; Al-Balwi M; Alzahrani M; Alaskar A; Hajeer A; Jawdat D
    HLA; 2017 Nov; 90(5):292-294. PubMed ID: 28731615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 Δ32 Homozygous Stem Cells.
    Verheyen J; Thielen A; Lübke N; Dirks M; Widera M; Dittmer U; Kordelas L; Däumer M; de Jong DCM; Wensing AMJ; Kaiser R; Nijhuis M; Esser S
    Clin Infect Dis; 2019 Feb; 68(4):684-687. PubMed ID: 30020413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines.
    Paxton WA; Liu R; Kang S; Wu L; Gingeras TR; Landau NR; Mackay CR; Koup RA
    Virology; 1998 Apr; 244(1):66-73. PubMed ID: 9581779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HIV: vision of a cure].
    Boffi el Amari E
    Rev Med Suisse; 2011 Oct; 7(312):1968, 1970-3. PubMed ID: 22097447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.
    Henrich TJ; Hanhauser E; Harrison LJ; Palmer CD; Romero-Tejeda M; Jost S; Bosch RJ; Kuritzkes DR
    J Infect Dis; 2016 Mar; 213(5):766-70. PubMed ID: 26512140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous Hematopoietic Stem Cells transplantation and genetic modification of CCR5 m303/m303 mutant patient for HIV/AIDS.
    Esmaeilzadeh A; Farshbaf A; Erfanmanesh M
    Med Hypotheses; 2015 Mar; 84(3):216-8. PubMed ID: 25613565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic stem cell transplantation for HIV cure.
    Kuritzkes DR
    J Clin Invest; 2016 Feb; 126(2):432-7. PubMed ID: 26731468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
    Tebas P; Jadlowsky JK; Shaw PA; Tian L; Esparza E; Brennan AL; Kim S; Naing SY; Richardson MW; Vogel AN; Maldini CR; Kong H; Liu X; Lacey SF; Bauer AM; Mampe F; Richman LP; Lee G; Ando D; Levine BL; Porter DL; Zhao Y; Siegel DL; Bar KJ; June CH; Riley JL
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of the HIV resistance CCR5-Delta32 allele among Egyptians and Syrians.
    Salem AH; Batzer MA
    Mutat Res; 2007 Mar; 616(1-2):175-80. PubMed ID: 17166523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
    Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
    J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C.
    Woitas RP; Ahlenstiel G; Iwan A; Rockstroh JK; Brackmann HH; Kupfer B; Matz B; Offergeld R; Sauerbruch T; Spengler U
    Gastroenterology; 2002 Jun; 122(7):1721-8. PubMed ID: 12055576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic expressions of CCR5-delta32/delta32 homozygosity.
    Nguyêñ GT; Carrington M; Beeler JA; Dean M; Aledort LM; Blatt PM; Cohen AR; DiMichele D; Eyster ME; Kessler CM; Konkle B; Leissinger C; Luban N; O'Brien SJ; Goedert JJ; O'Brien TR
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):75-82. PubMed ID: 10534150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population.
    Takácová M; Nogová P; Hábeková M; Staneková D
    Acta Virol; 2008; 52(4):261-4. PubMed ID: 19143484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation.
    Prator CA; Donatelli J; Henrich TJ
    Curr HIV/AIDS Rep; 2020 Aug; 17(4):385-393. PubMed ID: 32519184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study.
    Salgado M; Gálvez C; Nijhuis M; Kwon M; Cardozo-Ojeda EF; Badiola J; Gorman MJ; Huyveneers LEP; Urrea V; Bandera A; Jensen BO; Vandekerckhove L; Jurado M; Raj K; Schulze Zur Wiesch J; Bailén R; Eberhard JM; Nabergoj M; Hütter G; Saldaña-Moreno R; Oldford S; Barrett L; Ramirez MLM; Garba S; Gupta RK; Revollo B; Ferra-Coll C; Kuball J; Alter G; Sáez-Cirión A; Diez-Martin JL; Duke ER; Schiffer JT; Wensing A; Martinez-Picado J;
    Lancet HIV; 2024 Jun; 11(6):e389-e405. PubMed ID: 38816141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
    Pippi F
    Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective effect of CCR5-Δ32 against HIV infection by the heterosexual mode of transmission in a Polish population.
    Zwolińska K; Knysz B; Rybka K; Pazgan-Simon M; Gąsiorowski J; Sobczyński M; Gładysz A; Piasecki E
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):54-60. PubMed ID: 22957692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.